Zobrazeno 1 - 10
of 162
pro vyhledávání: '"Spero R. Cataland"'
Publikováno v:
Hematology Reports, Vol 15, Iss 3, Pp 518-523 (2023)
Avatrombopag is a novel oral non-peptide thrombopoietin receptor agonist (TPO-RA) that was approved by the FDA as a second-line therapy for chronic immune thrombocytopenia (cITP). Avatrombopag has shown promising results in regards to efficacy and to
Externí odkaz:
https://doaj.org/article/bb2da32d639f4c9987fbc59ba01a96bc
Publikováno v:
Research and Practice in Thrombosis and Haemostasis, Vol 6, Iss 1, Pp n/a-n/a (2022)
Abstract De novo and relapsed immune‐mediated thrombotic thrombocytopenic purpura (iTTP) have been documented to have occurred following severe acute respiratory syndrome coronavirus 2 (COVID‐19) vaccination. Here, we present a case of a 28‐yea
Externí odkaz:
https://doaj.org/article/2a0471bca37d4ae28c71f968d896ef13
Autor:
Eric Rondeau, Spero R. Cataland, Imad Al-Dakkak, Benjamin Miller, Nicholas J.A. Webb, Daniel Landau, MD
Publikováno v:
Kidney International Reports, Vol 4, Iss 11, Pp 1568-1576 (2019)
Introduction: Eculizumab has transformed outcomes for patients with atypical hemolytic uremic syndrome (aHUS). Its efficacy and safety profile was well characterized in the clinical trial program. The long-term safety profile was not previously asses
Externí odkaz:
https://doaj.org/article/f4c30169aad14443b7d1e00854abb943
Autor:
Spero R. Cataland, Peter J. Kourlas, Shangbin Yang, Susan Geyer, Leslie Witkoff, Haiwa Wu, Camila Masias, James N. George, Haifeng M. Wu
Publikováno v:
Blood Advances, Vol 1, Iss 23, Pp 2075-2082 (2017)
Abstract: Although steroids are routinely used as an adjunct to plasma exchange (PEX) therapy in the treatment of immune-mediated thrombotic thrombocytopenic purpura (iTTP), limited data regarding their efficacy or effect on ADAMTS13 biomarkers are a
Externí odkaz:
https://doaj.org/article/57c9c790de8a4a33af482fe0b5ef21e5
Publikováno v:
Case Reports in Hematology, Vol 2015 (2015)
Complement-mediated hemolytic uremic syndrome (otherwise known as atypical HUS) is a rare disorder of uncontrolled complement activation that may be associated with heart failure. We report the case of a 49-year-old female with no history of heart di
Externí odkaz:
https://doaj.org/article/18b9b0d9a4314d10a53570df6f451932
Autor:
X. Long Zheng, Haifeng M. Wu, Dezhi Shang, Erica Falls, Christopher G. Skipwith, Spero R. Cataland, Charles L. Bennett, Hau C. Kwaan
Publikováno v:
Haematologica, Vol 95, Iss 9 (2010)
Background Type G immunoglobulins against ADAMTS13 are the primary cause of acquired (idiopathic) thrombotic thrombocytopenic purpura. However, the domains of ADAMTS13 which the type G anti-ADAMT13 immunoglobulins target have not been investigated in
Externí odkaz:
https://doaj.org/article/73de22e33cf847be80ef90d8902c2dd2
Autor:
Shruti, Chaturvedi, Ana G, Antun, Andrew M, Farland, Ryan, Woods, Ara, Metjian, Yara A, Park, Gustaaf, de Ridder, Briana, Gibson, Raj S, Kasthuri, Darla K, Liles, Frank, Akwaa, Todd, Clover, Lisa, Baumann Kreuziger, J Evan, Sadler, Meera, Sridharan, Ronald S, Go, Keith R, McCrae, Harsh Vardhan, Upreti, Angela, Liu, Ming Y, Lim, Radhika, Gangaraju, X Long, Zheng, Jay S, Raval, Camila, Masias, Spero R, Cataland, Andrew, Johnson, Elizabeth, Davis, Michael D, Evans, Marshall A, Mazepa
Publikováno v:
Blood. 140:1335-1344
Immune-mediated thrombotic thrombocytopenic purpura (iTTP) is characterized by recurring episodes of thrombotic microangiopathy, causing ischemic organ impairment. Black patients are overrepresented in iTTP cohorts in the United States, but racial di
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8bc4cc94bbaac641f87df27b51dd51a7
https://doi.org/10.1182/blood.2022016640
https://doi.org/10.1182/blood.2022016640
Publikováno v:
Blood. 140:438-444
Immune-mediated thrombocytopenic purpura (iTTP) is a thrombotic microangiopathy characterized by an acquired ADAMTS13 deficiency as a result of the presence of an antibody inhibitor of ADAMTS13 leading to the formation of ultralarge von Willebrand mu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f3a7a5ec6c51ccf51d2cd01e893d748a
https://doi.org/10.1182/blood.2021014514
https://doi.org/10.1182/blood.2021014514
Autor:
John Trinidad, Benjamin H. Kaffenberger, Jessica A. Kaffenberger, Spero R. Cataland, Steven M Dean, Kelsey B. Nusbaum, Kelly Tyler, Abraham M. Korman
Publikováno v:
Journal of the American Academy of Dermatology. 85:301-310
The skin often provides initial clues of hypercoagulability with features such as livedo reticularis, livedo racemosa, retiform purpura, necrosis, and ulcerations. Because these cutaneous manifestations are nonspecific, laboratory testing is often ne
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d20e6485a771c8bcdd4c5078e992e241
https://doi.org/10.1016/j.jaad.2021.03.108
https://doi.org/10.1016/j.jaad.2021.03.108
Autor:
Paul Knoebl, Javier de la Rubia, Filip Callewaert, Hilde De Winter, Johanna A. Kremer Hovinga, Spero R. Cataland, Marie Scully, Katerina Pavenski, Jessica Minkue Mi Edou, Flora Peyvandi, Ara Metjian, Paul Coppo
Publikováno v:
Blood Adv
The efficacy and safety of caplacizumab in individuals with acquired thrombotic thrombocytopenic purpura (aTTP) have been established in the phase 2 TITAN and phase 3 HERCULES trials. Integrated analysis of data from both trials was conducted to incr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::08b1f9e0649eea658a8348966f9df48d
https://doi.org/10.1182/bloodadvances.2020001834
https://doi.org/10.1182/bloodadvances.2020001834